Stifel resumed coverage on Senseonics with a new price target
$SENS
Medical/Dental Instruments
Health Care
Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $9.00 | Hold | Stifel |
| 8/27/2025 | $1.50 | Overweight | Barclays |
| 7/15/2025 | $1.25 | Buy | TD Cowen |
| 6/2/2025 | $1.10 | Buy | H.C. Wainwright |
| 4/10/2025 | $2.00 | Outperform | Mizuho |
| 7/19/2023 | $0.50 | Underperform | Jefferies |
| 8/19/2021 | $6.00 | Buy | HC Wainwright & Co. |
Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00
Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50
TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
SD - Senseonics Holdings, Inc. (0001616543) (Filer)
S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Even
The new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is expected to launch in the second half of 2026 GERMANTOWN, Md. and COLUMBIA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Senseonics, a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, and Welldoc®, a leader in AI-powered health solutions, today announce a strategic partnership to develop a new custom mobile application for Eversense® 365. The next-generation app will maintain all existing features that patients currently benefit from, alongside new features to enhance user exp
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance New data expands on findings shared at ATTD and reinforces Eversense 365's strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Even
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase